Northern Trust Corp decreased its position in Haleon PLC Sponsored ADR (NYSE:HLN - Free Report) by 5.8% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 5,098,844 shares of the company's stock after selling 313,698 shares during the period. Northern Trust Corp owned approximately 0.11% of Haleon worth $52,467,000 as of its most recent SEC filing.
Several other institutional investors and hedge funds have also recently bought and sold shares of the company. Nuveen LLC bought a new position in Haleon in the 1st quarter worth about $58,870,000. Point72 Asset Management L.P. bought a new stake in shares of Haleon during the 4th quarter worth about $45,110,000. Bain Capital Public Equity Management II LLC raised its position in shares of Haleon by 6.2% during the 4th quarter. Bain Capital Public Equity Management II LLC now owns 2,844,010 shares of the company's stock worth $27,132,000 after buying an additional 165,929 shares in the last quarter. Royal Bank of Canada raised its position in shares of Haleon by 62.6% during the 4th quarter. Royal Bank of Canada now owns 2,733,615 shares of the company's stock worth $26,078,000 after buying an additional 1,052,462 shares in the last quarter. Finally, Natixis Advisors LLC raised its position in shares of Haleon by 25.5% during the 1st quarter. Natixis Advisors LLC now owns 1,917,548 shares of the company's stock worth $19,731,000 after buying an additional 390,156 shares in the last quarter. Institutional investors own 6.67% of the company's stock.
Wall Street Analyst Weigh In
A number of research firms have commented on HLN. Morgan Stanley upgraded shares of Haleon from an "equal weight" rating to an "overweight" rating and set a $11.25 price target on the stock in a research report on Friday, May 9th. Wall Street Zen lowered shares of Haleon from a "buy" rating to a "hold" rating in a research report on Saturday, July 12th. Barclays restated an "overweight" rating on shares of Haleon in a research report on Tuesday, May 6th. BNP Paribas Exane upgraded shares of Haleon from a "neutral" rating to an "outperform" rating and set a $13.40 price objective for the company in a research report on Tuesday, May 27th. Finally, BNP Paribas upgraded shares of Haleon to a "strong-buy" rating in a research report on Tuesday, May 27th. Two analysts have rated the stock with a Strong Buy rating, three have given a Buy rating and four have assigned a Hold rating to the company's stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $12.33.
Get Our Latest Research Report on HLN
Haleon Trading Up 1.2%
Shares of HLN traded up $0.12 during midday trading on Friday, hitting $9.81. The stock had a trading volume of 8,278,049 shares, compared to its average volume of 8,696,741. Haleon PLC Sponsored ADR has a fifty-two week low of $8.86 and a fifty-two week high of $11.42. The business has a 50-day simple moving average of $9.85 and a two-hundred day simple moving average of $10.21. The firm has a market cap of $43.97 billion, a P/E ratio of 25.14, a price-to-earnings-growth ratio of 2.89 and a beta of 0.23. The company has a current ratio of 0.87, a quick ratio of 0.63 and a debt-to-equity ratio of 0.48.
Haleon Increases Dividend
The firm also recently disclosed a semi-annual dividend, which will be paid on Thursday, September 18th. Shareholders of record on Friday, August 15th will be given a dividend of $0.0555 per share. This represents a yield of 190.0%. The ex-dividend date is Friday, August 15th. This is a boost from Haleon's previous semi-annual dividend of $0.05. Haleon's dividend payout ratio is 28.21%.
About Haleon
(
Free Report)
Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.
Featured Stories

Before you consider Haleon, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Haleon wasn't on the list.
While Haleon currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.